Ebglyss
Provider 
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public

A selective IL-13 inhibitor approved for atopic dermatitis in patients aged six and older.
Ebglyss (lebrikizumab-lbkz) is a selective interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis in patients aged six and older. It demonstrated positive Phase 3 outcomes by selectively blocking IL-13 signaling, a key driver of type 2 inflammation in atopic dermatitis.
Developed by Eli Lilly and Company, Ebglyss offers a subcutaneous treatment option for patients who have not responded adequately to topical therapies, providing an alternative mechanism to existing IL-4R inhibitors in the atopic dermatitis biologics landscape.
AbCellera Biologics

Abcl575
abcellera.com
Enveda Biosciences

ENV-294
enveda.com
Triveni Bio

Triv-509, Triv-573
triveni.bio
| Attribute | Ebglyss | Abcl575 | ENV-294 | Triv-509, Triv-573 | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 1876 | 2012 | 2019 | 2023 | |
| Sells To | Consumers, Enterprise | Enterprise, Government | Enterprise | B2B, Enterprise | |
| Pricing Model | Recurring, Software, Transactional | Recurring, Software | Recurring | Licensing, Pre-Revenue | |
| Ownership | Public | Public | Venture-backed | Private, Venture-backed |
Provider 
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider 
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2019
Sells To Enterprise
Pricing Model Recurring
Ownership Venture-backed
Provider 
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed


A monoclonal antibody that inhibits IL-4R signaling, approved for atopic dermatitis and other inflammatory conditions.

Rinvoq is a AbbVie product.
